“Investors in biotech stocks need to find targets with positive catalysts on the near- to mid-term horizon, including promising drug candidates and/or novel approaches to unmet medical needs.”
Regarding the two stocks he highlights, the author of today’s article declares “these two small-caps are both first movers in healthcare sectors that are ripe for disruption, with massive opportunities over the next decade.”
RAS mutations are the initiating genetic events in many cancers – and have proven to be extremely difficult to target. With its lead compound, however, the oncology company featured in today’s article is “looking to become the backbone of treatment for RAS-driven cancers.
Is the current downturn a good buying opportunity for biotech stocks? And, if so, which biotech stocks are the most promising picks for aggressive investors?
Two clinical-stage biotech stocks with the potential to deliver gains of 100% or more.
Why might the stock highlighted in today’s article – shares of which have more than tripled investors’ money over the past year – be the… Read More »3 Reasons This Could Be “The Best Biotech Stock You Can Buy At The Moment”
When it comes to the five biotech penny stocks to watch this quarter highlighted in today’s article, the author emphasizes that “These aren’t just names… Read More »There’s Good Reason To Watch These 5 Biotech Penny Stocks This Quarter
While large-cap biotech stocks may come with less risk than their small-cap counterparts, the author of today’s article notes that “On the plus side small-cap… Read More »10 Under $10: The Best Small-Cap Biotech Stocks For 2021
Which developmental-stage biotechs have the potential to beat the difficult odds and successfully get their novel drugs to market?